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Abstract: Unmethylated cytosine-phosphate-guanosine (CpG) oligodeoxynucleotides (ODNs) 
are recognized by Toll-like receptor 9 (TLR9) found in antigen-presenting cells and B cells 
and can activate the immune system. Using CpG ODNs as an adjuvant has been found to be 
effective for treating infectious diseases, cancers, and allergies. Because natural ODNs with only 
a phosphodiester backbone are easily degraded by nuclease (deoxyribonuclease [DNase]) in 
serum, CpG ODNs with a phosphorothioate backbone have been studied for clinical application. 
CpG ODNs with a phosphorothioate backbone have raised concern regarding undesirable side 
effects; however, several CpG ODNs with only a phosphodiester backbone have been reported 
to be stable in serum and to show an immunostimulatory effect. In recent years, research has 
been conducted on delivery systems for CpG ODNs using nanoparticles (NPs). The advantages 
of NP-based delivery of CpG ODN include (1) it can protect CpG ODN from DNase, (2) it 
can retain CpG ODN inside the body for a long period of time, (3) it can improve the cellular 
uptake efficiency of CpG ODN, and (4) it can deliver CpG ODN to the target tissues. Because 
the target cells of CpG ODN are cells of the immune system and TLR9, the receptor of CpG 
ODN is localized in endolysosomes, CpG ODN delivery systems are required to have qualities 
different from other nucleic acid drugs such as antisense DNA and small interfering RNA. Studies 
until now have reported various NPs as carriers for CpG ODN delivery. This review presents 
DNase-resistant CpG ODNs with various structures and their immunostimulatory effects and 
also focuses on delivery systems of CpG ODNs that utilize NPs. Because CpG ODNs interact 
with TLR9 and activate both the innate and the adaptive immune system, the application of CpG 
ODNs for the treatment of cancers, infectious diseases, and allergies holds great promise.
Keywords: Toll-like receptor 9 (TLR9), immunostimulation, higher-order nanostructure of 
DNA, delivery system, nanoparticles
Introduction
Unmethylated cytosine-phosphate-guanosine (CpG) dinucleotide is recognized by 
Toll-like receptor 9 (TLR9) and induces immune response. Immune activity in DNA 
was first discovered when a DNA fraction of Bacille Calmette-Guérin was found to 
produce type I interferon (IFN), leading to the activation of natural killer cells; the 
antitumor effect of this induction was recognized.1 Krieg et al2 elucidated that immune 
response is caused only when CpG is included in the DNA, and that immune response 
is inactivated when the cytosine residue is methylated. This CpG sequence is found 
with high frequency in bacterial DNA, and only occasionally in mammalian DNA. 
Because CpG in mammalian DNA is methylated, it is believed that the recognition of 
unmethylated CpG sequence is an action by the immune system to recognize the DNA 
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of bacteria and eliminate it. It was then discovered that TLR9 
is the receptor of DNA containing unmethylated CpG.3
In human beings, TLR9 is mainly expressed by B cells 
and plasmacytoid dendritic cells (pDCs).4 CpG stimulates 
these cells and induces innate and adaptive immune responses 
(Figure 1). B cells whose TLR9 is activated by CpG secrete 
cytokines important to the innate immune system – including 
IL-6, IL-10, and IL-12 – using nuclear factor-kappa B and 
other signal transduction pathways.2,5,6 IL-6 and IL-12 secreted 
from B cells are also involved in adaptive immune response. 
IL-6 promotes the multiplication and activation of B cells; as 
a result, the production of antibodies is enhanced.7,8
pDCs whose TLR9 is activated by CpG secrete cytokines 
involved in innate immune response, including type I IFNs 
and tumor necrosis factor-alpha (TNFα).9 These pDCs also 
activate natural killer cells.10 Furthermore, pDCs with acti-
vated TLR9 secrete IL-12 and promote the differentiation 
of T helper (Th) 0 into Th1,11–13 as well as inducing Th1 to 
migrate to B cells through the actions of IFN-γ-inducible 
protein of 10 kDa (IP10).14,15 B cells that interact with Th1 
differentiate into plasma cells, which possess the ability 
to produce antibodies, playing a central role in adaptive 
immunity. Also, IFN-α promotes CD8-positive cytotoxic T 
lymphocyte response.16,17
Because immune response mediated by the activation of 
TLR9 induces not only the innate immune system but also 
the adaptive immune system, its application for treating 
illnesses including infectious diseases, cancers, allergies, 
and asthma holds great promise.18–21 Until now, various 
CpG oligodeoxynucleotides (ODNs) have been developed 
to induce immune response via the activation of TLR9. What 
is most important in the clinical application of CpG ODN 
is protecting CpG ODN from DNase and delivering CpG 
ODN to the TLR9 of pDCs. Chemical modification of CpG 
ODN is an effective technique to protect against degradation 
by DNase. However, several severe side effects caused by 
the modification of DNA backbone have been reported. For 
example, repeated administration of backbone-modified CpG 
ODNs has resulted in reduced immune responses, lymphoid 
follicle destruction, and organ enlargement.22 DNase-resistant 
natural CpG ODNs consisting entirely of phosphodiester 
backbone are, therefore, desirable for clinical application, 
but so far most clinical trials have been conducted using 
backbone-modified CpG ODNs. Encapsulating CpG ODN 
and sealing it inside nanoparticles (NPs) is also an effective 
method to protect ODN against break down by DNase. NPs 
may make it possible to use naturally occurring CpG ODNs 
in clinical applications.
IL-6 and IL-10
secretion
Innate immune response
CpG ODN
Adaptive immune response
IL-12
IL-12
IP-10
Th0
Th0
Th1
IL-2
Plasma cell
IgG secretion
Inhibition of IgE production
CD8+ cytolytic T lymphocyte (CTL)
IL-6
B cell
IFN-γ
IFN-α
IFN-α/β and
TNFα
secretion
Plasmacytoid
dendritic cell
(pDC)
Natural killer cells
Figure 1 Immunostimulatory effect of cytosine-phosphate-guanosine (CpG) oligodeoxynucleotides (ODNs). 
Notes: The immunomodulatory cascade triggered by CpG ODNs includes the activation of T helper 1 (Th1) cells and secretion of proinflammatory cytokines such as 
interleukin (IL)-6, IL-12, and interferon gamma (IFN-γ). The CpG motifs in either bacterial DNA or synthetic CpG ODNs act as “danger signals” to the innate immune system, 
triggering a protective immune response against the pathogen. In addition, the adaptive immune response mounted by the host afterward will maintain an immunologic 
memory and provide long-lasting protection. 
Abbreviation: TNFα, tumor necrosis factor-alpha.
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Delivery systems for CpG ODNs using NPs as carriers 
differ greatly from delivery systems for anticancer drugs 
and nucleic acid drugs such as antisense DNA and small 
interfering RNA (siRNA). For delivery of anticancer drugs 
using NPs, the NPs must be delivered from the bloodstream 
to the cancerous tissues through vascular walls. Therefore, 
NPs of around 100 nm in size are required. Also, manipula-
tion is required so that immune cells do not capture the NPs 
before they arrive at cancerous tissues. The target cells for 
the delivery of CpG ODN, on the other hand, are antigen-
presenting cells (APCs) and B cells. These immune cells 
easily take up relatively large particles, greater than 100 nm 
in size.23 For delivery of antisense DNA and siRNA, after 
they have been taken up by cells as a result of endocytosis, 
their nucleic acids must move from the endosome to the 
nucleus. However, with the delivery of CpG ODN, because 
the receptor TLR9 is localized in the endosome, CpG ODNs 
must be retained in the endosome for a long period of time. 
Therefore, delivery systems using CpG ODNs require a 
design strategy different from that of conventional drug 
delivery systems.
This review summarizes the structural features that 
depend on base sequences of CpG ODNs consisting of 
phosphorothioate and phosphodiester backbones and 
considers their relationship to the capacity of immune 
mediator cytokine induction. In addition, this review also 
considers the advantages and disadvantages in a delivery 
system of these CpG ODNs using various NPs as carriers 
and describes the possible future direction of studies on 
CpG ODNs.
Synthetic CpG ODNs with 
various structures and their 
immunostimulatory effect
DNase-resisitant CpG ODNs  
for TLR9 activation
Because ODNs that contain CpG motifs are quickly degraded 
by DNase, research has been conducted on CpG ODNs resis-
tant to DNase.24–30 DNase-resistant CpG ODNs consisting 
of a phosphorothioate backbone have been developed by 
replacing the oxygen in the phosphate group of the nucleic 
acid targeted by DNase.24,25,31 These chemically modified 
synthetic CpG ODNs are divided into at least four classes 
(Table 1 and Figure 2).
Class A (also known as type D) CpG ODN has a naturally 
occurring phosphodiester backbone and palindromic CpG 
motifs at the center of its sequence. Poly(G) sequences 
on phosphorothioate backbones are attached to the 3′ and 
5′ ends.32–34 This class of CpG ODN activates the TLR9 
of pDCs and induces IFN-α. However, it almost never 
induces the multiplication of B cells. The entire sequence of 
class B (type K) CpG ODN consists of a phosphorothioate 
backbone.33–36 This class of CpG ODN induces the 
proliferation and activation of B cells. However, its ability 
to induce IFN-α with pDCs is low.37 Class C includes 
Table 1 Features of each class of cytosine-phosphate-guanosine (CpG) oligodeoxynucleotides (ODNs)
Class A (type D) Class B (type K) Class C Class P
ODN structure Central phosphodiester region  
containing one or more CpG motifs  
in a palindrome and 5′ and/or 3′ ends  
consisting of poly(G) motifs with  
phosphorothioate backbone
Completely  
phosphorothioate backbone
One or more 5′ CpG  
motif(s) and a  
3′ palindrome
Two palindromes consisting  
of phosphorothioate backbone
Examples ODN2216 (for human) 
ODN2336 (for human) 
ODN1585 (for mouse)
ODN2006 (also know as  
PF-3512676 and CpG7909,  
for human) 
ODN1668 (for mouse) 
ODN1826 (for mouse)
ODN2395  
(for human and mouse) 
ODN M362  
(for human and mouse)
ODN21798
Mainly stimulated  
cell types
pDCs B cells pDCs and B cells pDCs
Actions Innate immune responses:  
IFN-α, TNFα, and IL-12 secretion
Innate immune responses:  
IL-6, IL-10, and  
IL-12 secretion
Intermediate between  
the A and B classes
Potency for IFN-α secretion  
is higher than that of  
CpG ODN in class C
Adaptive immune responses:  
IL-12 and IP10 secretion
Adaptive immune responses:  
antibody production;  
IL-6 and IL-12 secretion
Abbreviations: IFNα, interferon-alpha; IL, interleukin; IP10, interferon-gamma-inducible protein of 10 kDa; pDC, plasmacytoid dendritic cell; TNFα, tumor necrosis factor-alpha.
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one or two CpG motif(s) with a phosphodiester backbone 
at the 5′ end, and contains a palindromic sequence on a 
phosphorothioate backbone at the 3′ end. This class of 
CpG ODN has the capacity to induce the proliferation of B 
cells and the production of IFN-α via pDCs; it has a quality 
between classes A and B.38–41 Also, class P CpG ODN has 
two palindromic motifs on phosphorothioate backbones. It 
displays a high capacity for producing IFN-α and the ability 
to activate nuclear factor-kappa B.42
These classes of CpG ODN include a complete or par-
tial phosphorothioate backbone, so that they are resistant to 
DNase. However, side effects are a cause for concern. Reports 
of side effects include the prolongation of coagulation time 
due to the inhibition of the tenase complex,43 distribution 
of cell signaling due to nonspecific adsorption of proteins 
including transcription factors,44 and acute toxicity due to 
complement activation.45,46 These classes of CpG ODN have 
also been reported to cause renal damage.47,48 Therefore, 
ideally, naturally occurring CpG ODNs consisting only 
of phosphodiester backbone is desired. Because DNA is 
mainly decomposed by exonucleases, it is believed that a 
ring structure like a plasmid is difficult to break down. When 
DNA with only a phosphodiester backbone was formed into 
a dumbbell-like structure, it certainly displayed resistance to 
DNase.49–51 Schmidt et al52 synthesized an ODN with a phos-
phodiester backbone in a dumbbell-like structure designed 
to include CpG motifs in hairpin-loops (Figure 3A). By 
utilizing the actions of peripheral blood mononuclear cells, 
immunostimulatory effects similar to linear-structure CpG 
ODNs with phosphorothioate backbones at both ends were 
obtained. Immunostimulatory activity that induces TNF-α 
and IL-6 is found in Y-shaped DNA (Y-DNA) itself, formed 
from three single-strand DNA having naturally occurring 
phosphodiester backbones.53 DNA with branch structures, 
like Y-DNA, has outstanding cellular uptake efficiency. 
However, it has no resistance to DNase. Rattanakiat et al30 
discovered that dendrimer-like DNA (DL-DNA) (Figure 3B) 
with phosphodiester backbones, formed by linking Y-DNA 
containing CpG motif, has high immunostimulatory   activity. 
One of the causes of this high activity is believed to be 
DL-DNA’s resistance to DNase. Recently, Nishikawa et al54 
observed that TNF-α release from RAW264.7 cells at 8 hours 
after stimulation by CpG motifs contained X-shaped DNA 
consisting entirely of phosphodiester backbone. This suggests 
that X-shaped DNA was stable for 8 hours at least, although 
Y-DNA has no resistance to DNase. Li et al55 synthesized 
the CpG-bearing DNA tetrahedral nanostructure with only 
a phosphodiester backbone (Figure 3C). The core tetrahedral 
structure comprised four 55-mer ODNs self-assembled with 
one another by an annealing process. CpG motif sequence 
was linked to each ODN via a 7-mer oligothiamine spacer. 
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Figure 3 Structures of cytosine-phosphate-guanosine (CpG) oligodeoxynucleotides 
(ODNs) consisting of entirely phosphodiester backbone. (A) Sequence and structure 
of CpG ODN with a dumbbell-like structure: the CpG ODN with a dumbbell-
like structure has 30 nucleotides in both loops that contain three CpG dinucleotide 
motifs.a (B) Structure of dendrimer-like DNA: Y-shaped DNA consists of three 
single-stranded  DNA  with  30  nucleotides  containing  CpG  dinucleotide  motifs; 
G1, G2, and G3 dendrimer-like structures were synthesized by ligation of Y-shaped 
DNA; the sizes of CpG ODNs with G1, G2, and G3 dendrimer-like structures 
were about 12, 20, and 36 nm, respectively.b (C) Assembly of CpG bearing DNA 
tetrahedral nanostructure: the core tetrahedral nanostructure consists of assembly 
with four 55-mer ODNs. The CpG motif is linked to each ODN via a 7-mer 
oligothyamine spacer.c 
aReproduced with permission from Schmidt et al;52  breproduced with permission 
from Rattanakiat et al30; creproduced with permission from Li et al.55
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Figure 2 Features of cytosine-phosphate-guanosine oligodeoxynucleotide (ODN) 
sequences in each class. 
Note: Underlining indicates palindromic sequence; black and red hyphens indicate 
phosphodiester and phosphorothioate bonds, respectively.
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The CpG-bearing DNA tetrahedral nanostructure was 
efficiently taken up into macrophage-like cells, and induced 
various pro-inflammatory cytokines such as TNF-α, IL-6, and 
IL-12 through TLR9 activation. Li et al55 also suggested that 
the stimulatory effect of the tetrahedral nanostructure is due 
to resistance to DNase, because the tetrahedral nanostructure 
DNA was stable in serum for 8 hours.
Furthermore, Meng et al56 discovered that linear-
structured CpG ODNs consisting only of a phosphodiester 
backbone possess high TLR9 activation capacity. TLR9 
activation by class B ODNs is most optimal when there are 
two to four CpG motifs. When four or more CpG motifs 
were linked, ODN consisting only of a phosphodiester 
backbone remarkably improved its resistance against 
DNase. The ODN contained nine or more CpG motifs, 
remained largely intact in serum for more than 24 hours, 
and possessed high TLR9 activation capacity even in low 
concentrations. Because DNA administered inside the 
body is cleaved from the 3′ end by exonuclease, when the 
3′ end of CpG ODN with only a phosphodiester backbone 
was modified, its resistance to DNase increased.56 When 
multiple CpG motifs are linked, even when the 3′ end is 
cleaved by exonuclease, the activation capacity of TLR9 
can be maintained when the cell is acted on because many 
CpG motifs still remain.
Structure-dependent immunostimulatory 
effect of synthetic CpG ODNs
Class A CpG ODNs induce the production of IFN-α by 
activating the TLR9 of pDC. However, class B ODNs do 
not induce the production of IFN-α via pDCs. This shows 
that the action of CpG ODNs is dependent on base sequence 
and structure.
Class A CpG ODNs form nanometer-sized multimers 
under certain physiological conditions and take on globular 
and linear structures (Figure 4A).57 This globular structure 
is split into two forks.57,58 This is because the structure forms 
a duplex because of the palindromic sequence of base pairs 
at the center of the ODN. Next, the four poly(G) sequences 
at the end of these duplexes combine with one another 
because of Hoogsteen base pairing and become a G-tetrad 
structure. As a result, they become G-quadruplex structures 
(Figure 4B). G-quadruplex can form a linear structure when 
it further forms a G-tetrad with another duplex (Figure 4B). 
Also, when two strands of monomeric CpG ODN combine 
with the G-quadruplex, there is a possibility that two-forked 
NPs can form (Figure 4C). In other words, class A CpG 
ODNs spontaneously form higher-order structures because 
of their palindromic sequence and poly(G). For class A CpG 
ODN2216, in the case of linear structure, its length is more than 
100 nm, and in the case of globular structure, the maximum 
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Figure 4 Formation of higher-order structure in class A oligodeoxynucleotides (ODNs). (A) Globular structure of class A cytosine-phosphate-guanosine (CpG) ODN 
observed by atomic force microscopy (large circled structure is a close-up view of small circle). (B) Possible higher-order structure formation of class A CpG ODNs. Class A 
CpG ODNs comprise a palindromic sequence in the center and poly(G) sequences at both the 5′ and the 3′ ends. Two monomer molecules form a duplex that is attributed 
to palindromic sequences. Two duplexes further form a quadruplex through G-tetrad formation of four poly(G) ends. Association of the quadruplex with another duplex 
causes a linear structure. Two other CpG monomers replace the original duplex by forming two new duplexes, which leads to formation of a bifurcation with three ends. 
(C) A bifurcation structure of class A CpG ODNs imaged by atomic force microscopy. (D) Height histogram of higher-order structure in class A CpG ODNs. 
Reproduced with permission from Klein et al.58
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size is 50 nm.57 Also, class A CpG ODN2336 has an average 
height of 0.8 ± 0.1 nm (Figure 4D) and length of 30–70 nm.58 
Meanwhile, such higher-order structures are not observed in 
class B CpG ODNs; they form a linear structure.58
Because poly(G) binds with scavenger receptors on 
the cell surface,59 ODNs that contain poly(G) sequences 
have been reported to show an increase in cellular uptake 
efficiency.34,60 This suggests that the high cellular uptake 
efficiency of class A CpG ODNs with poly(G) also means a 
high TLR9 activation capacity. On the other hand, Kerkmann 
et al57 reported that the cellular uptake efficiency of class A 
and class B CpG ODNs did not change. They suggested that 
the greater ability of class A CpG ODNs to produce IFN-α 
than class B CpG ODNs is because of the higher-order 
structure of class A CpG ODNs. This is because when the 
palindromic sequence is changed, higher-order structures are 
not formed, and the ability to produce to IFN-α is decreased. 
Furthermore, it has been observed that when class B CpG 
ODNs were loaded onto polystyrene NPs 180 nm in diameter, 
their production capacity of IFN-α was greater than that of 
class A CpG ODNs.57 Because the cellular uptake efficiency 
of free class B CpG ODNs loaded onto polystyrene NPs do 
not change, it is believed that the high IFN-α production 
capacity of class A CpG ODNs is due to its spontaneously 
formed higher-order structure. Other research groups have 
reported that by artificially causing class B CpG ODNs to 
form higher-order structures using NPs, an immune profile 
similar to class A CpG ODNs could be obtained.61–63 Class C 
CpG ODNs also form a duplex, because of the palindromic 
sequence at the 3′ end. This structure is believed to affect 
the activation of TLR9.
Naturally occurring DL-DNA containing CpG motifs 
synthesized as Y-DNA structural units displayed high 
immunostimulatory activity.30 The hydrodynamic size 
of Y-DNA formed from three-strand 30-base ODN was 
7.0 ± 0.2 nm; however, second- and third-generation 
DL-DNA (Figure 3B) were 20 ± 1.2 nm and 35.8 ± 3.2 nm, 
respectively. Receptor-mediated endocytosis is dependent on 
the size of ligands, and the optimal size for uptake is known 
to be 25–30 nm.64–67 The size of DL-DNA falls within this 
range, so its high immunostimulatory activity may have an 
effect on cellular uptake efficiency in addition to resistance 
to DNase. What is extremely interesting is that Y-DNA has 
immunostimulatory activity even if it does not contain CpG 
motifs.54 This suggests the importance of the higher-order 
structure of ODNs on immunostimulation.
Meng et al56 reported that ODNs consisting only of 
a phosphodiester backbone and linked with numerous 
CpG motifs exhibited high TLR9 production capacity. 
CpG ODN2006, a class B prototype, includes three CpG 
motifs. PD-ODN2006 is synthesized with a phosphodiester 
backbone, not the phosphorothioate backbone of the original 
ODN2006 sequence, and it has no TLR9 activation capacity 
because DNase degrades it. PD-ODN2006-2006, composed 
of two PD-ODN2006s linked together, is not degraded 
much by DNase and possesses high TLR9 activation capac-
ity (Figure 5). When the size of the DNA is below 250 
bases,   cellular uptake efficiency increases as the DNA size 
increases.68 However, a sequence that indirectly connects 
PD-ODN2006s using a 14-mer ligand sequence without a 
CpG dinucleotide sequence (PD-2006-linker-2006) showed 
lowered TLR9 activation capacity (Figure 5). PD-ODN2006-
2006 and PD-ODN2006-linker-2006 both contain six CpG 
motifs. The difference in TLR9 activation capacity despite 
this characteristic suggests that aside from the number of 
CpG motifs and size, TLR9 activation is also dependent on 
the ODN sequence.
Delivery of CpG ODNs using NPs
Control of the immune system via TLR9 by CpG ODNs has 
been shown to be effective for treating infectious diseases, 
cancers, and allergies. In recent years, various NPs have 
been developed as carriers of CpG ODNs. The number of 
papers related to the delivery of CpG ODNs using NPs has 
increased sharply since 2007.
The advantages of using NPs as CpG ODN carriers 
include (1) protection from DNase degradation, (2) extension 
of retention time inside the body, (3) decrease in the amount 
administered because cellular uptake efficiency is improved, 
(4) the ability to change the structure of CpG ODNs, (5) the 
ability to deliver to target tissues, (6) the ability to change 
localization inside the body, and (7) allow the slow release 
of CpG ODNs over a long period of time.
Protection of CpG ODNs  
from degradation by DNase
Concerning the protection of CpG ODNs from DNase 
by NPs, many research studies use CpG ODNs with a 
phosphorothioate backbone resistant to DNase, so there is 
little direct evidence available. Because antisense ODNs 
encapsulated by cationic lipid NPs or lipid NPs have been 
reported to be partially or completely protected from 
DNase degradation in serum,69,70 CpG ODNs with only 
phosphodiester backbone are believed to have similar effects 
when encapsulated by these nanopaNPsrticles. Zhu et al71 
showed that CpG ODNs with only a phosphodiester backbone 
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joined electrostatically to the surface of NPs acquired 
resistance to DNase degradation. They observed that all 
molecules of CpG ODNs with a completely phosphodiester 
backbone were broken down within an hour in 20% 
serum. However, CpG ODNs attached electrostatically to 
mesoporous silica NPs, the surface of which were modified 
with amino groups, remained after 3 hours without being 
degraded (Figure 6). Furthermore, when the conjugate of 
these NPs and CpG ODNs was coated with poly(allylamine 
hydrochloride), the efficiency of protection against DNase 
was discovered to increase. In vivo mice experiments have 
shown that 272 nm cationic poly(D,L-lactic-co-glycolic acid) 
(PLGA) NPs were taken up into pDCs in less than an hour,72 
so that protection of CpG ODNs against DNase by NPs for 
several hours is considered to be sufficient. The greatest 
advantage of using NPs is protection against DNase, as CpG 
ODNs consisting of chemically unmodified phosphodiester 
backbone can be used.
Prolonged circulation time and increased 
cellular uptake
In vivo experiments have reported that NPs prolong the 
circulation lifetime of CpG ODNs in the body. Pan et al73 
included a CG sequence in an 18-mer antisense ODN 
for controlling the Bcl-2 gene and discovered that this 
could activate the immune system. When free antisense 
ODN with phosphorothioate backbone was administered 
intravenously to mice, only 1% remained in plasma after 
24 hours. When this antisense ODN was encapsulated in 
lipid NPs (89 ± 45 nm in diameter) composed of 3β-[N,N-
(dimethylaminoethane)carbamoyl] cholesterol (DC-Chol), 
egg yolk phosphatidylcholine, distearoylphosphatidylethano
lamine-N-[methoxy(polyethylene glycol)-2000] (mPEG2000-
DSPE), and protamine, 25% of the ODN remained in plasma 
after 24 hours. This shows that encapsulation in lipid NPs 
extends blood circulation time. DC-Chol, a cationic lipid, 
partially deprotonates in near-neutral pH and decreases the 
surface electrical charge of NPs. Also, mPEG2000-DSPE 
on the surface of NPs decreases the uptake of NPS by 
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9 (TLR9) activation.a (Original ODN2006 consists entirely of phosphorothioate backbone, but the backbones of all the CpG ODNs used in this experiment were replaced 
by naturally occurring phosphodiester bonds.) (A) Activation of TLR9 represented by nuclear factor-kappa B (NF-κB) activity: 293XL-hTLR9 cells were stimulated by series 
connection of PD-ODN2006 with and without linker sequences. PD-ODN2006-2006, composed of two phosphodiester ODN2006s directly linked together, showed 
higher capacity for TLR9 activation than PD-ODN2006-A-2006 and PD-ODN2006-B-2006, whose sequences consist of indirectly connected phosphodiester ODN2006s 
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Notes: aThe sequence of ODN2006 that contains three CpG motifs is shown in Figure 2. 
Reproduced with permission from Meng et al.56
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Figure 6 Mesoporous silica nanoparticles (NPs) for delivery of natural cytosine-
phosphate-guanosine  (CpG)  oligodeoxynucleotides  (ODNs)  consisting  entirely 
of phosphodiester backbone. (A) Scanning electron microscopic image of amino-
modified mesoporous silica SBA-15 particles. (B) Stability of CpG ODNs consisting 
entirely of phosphodiester backbone in 20% serum containing medium: lane 1, DNA 
marker;  lane  2,  undigested  CpG  ODN  consisting  entirely  of  phosphorothioate 
backbone; lanes 3 and 4, free natural CpG ODN after incubation for 1 and 3 hours; 
lanes 5 and 6, natural CpG ODN loaded on mesoporous silica NPs after incubation 
for 1 and 4 hours; and lanes 7 and 8, natural CpG ODN loaded on mesoporous 
silica NPs followed by polycation (poly(allylamine hydrochloride)) treatment after 
incubation for 1 and 3 hours. This indicates that natural CpG ODN consisting entirely 
of phosphodiester backbone loaded on mesoporous silica NPs was stable in serum. 
Reproduced with permission from Zhu et al.71
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the reticuloendothelial system. These actions are believed 
to prolong the blood circulation time. When this lipid 
NP-encapsulated antisense ODN was administered, the 
cumulative dose to tumorous tissues was about nine times 
that of free ODN. Traditional cationic lipid NPs are quickly 
eliminated from the circulatory system,45 but if the electrical 
charge on the NPs’ surface is reduced, as in the case 
of DC-Chol, circulation time can be extended. Wilson 
et al27 discovered neutral cationic lipid NPs ionizable at 
physiological pH. When ionizable cationic lipid NPs and 
ODN are mixed under a low pH condition, the surface of 
the NPs becomes charged, and the ODN is electrostatically 
attached. Next, when these NPs are transferred to 40% 
ethanol, the structure of the NPs becomes unstable and 
ODN is taken up into the interior of the NPs. Afterwards, 
when the pH is made neutral, the NPs become neutral NPs. 
In contrast to the free ODN circulation lifetime of a few 
minutes, the circulation lifetime of ODN encapsulated in 
ionizable cationic lipid NPs can be extended from several 
hours to several days.74,75
One of the reasons that CpG ODNs adsorbed into NPs or 
with encapsulated phosphorothioate backbone show greater 
TLR9 activity than free CpG ODNs is that the cellular uptake 
efficiency of CpG ODNs is improved. The cellular uptake 
efficiency of CpG ODNs is being studied using fluorescently 
labeled CpG ODNs. When fluorescently labeled free CpG 
ODN was added to cultured 239XL-TLR9 cells, fluores-
cence was not observed inside the cells. In contrast, strong 
fluorescence was observed in CpG ODN adsorbed by mes-
oporous silica NPs and boron nitride NPs (Figure 7).71,76 In 
vivo studies have shown the method of delivering CpG ODN 
using lipid NPs significantly increased uptake efficiency 
compared with free CpG ODN when it was administered 
to mice and the uptake into APCs in the spleen and lymph 
nodes was observed after 24 hours.27 Also, when CpG ODNs 
were loaded onto cationized gelatin NPs with an average 
diameter of 272 ± 33.3 nm, after 2 days DCs in draining 
lymph nodes were 30% CpG positive and B cells were 20% 
positive.77 The cause is believed to be the increase in the 
delivery efficiency of CpG ODNs by NPs, with many CpG 
ODNs being adsorbed or encapsulated per NP. Klier et al78 
also reported that class A CpG ODN delivered by gelatin 
NPs showed significant immunomodulation effect (Th2/
Th1 shift) on equine bronchoalveolar lavage cells. This effect 
is believed to be an enhancement of cellular uptake of CpG 
ODNs by gelatin NPs.
Clathrin-mediated endocytosis, caveolae-mediated 
uptake, phagocytosis, macropinocytosis, and clathrin- and 
caveolae-independent endocytosis are all possible methods 
for the uptake of lipid NPS into cells. The specific method 
depends on the type of cells.27 When free CpG ODNs were 
charged negatively, it was difficult for them to attach to a 
negatively charged cell surface. This electrostatic repulsion is 
believed to limit the efficiency of free CpG ODN uptake.
The size of NPs affects both cellular uptake and TLR9 
activation. Foged et al23 investigated phagocytic activity on 
DCs by polystyrene NPs of various sizes from 0.04 to 15 µm, 
and reported that the size of 500 nm was optimal for uptake 
into DCs. Also, when the NP size was greater than 200 nm, 
it was reported that the retention time in the endosome was 
long. However, NPs form aggregates or agglomerates in   
solution. When NPs form aggregates or agglomerates, cells 
take in not only NPs by themselves but also NPs in aggregates 
or agglomerates. Therefore, not the primary size of NPs but 
their hydrodynamic size should be used as the indicator of 
the effects of the size of NPs on cellular uptake.
Retention of NPs loaded with CpG 
ODNs in endolysosome
TLR9 joins with CpG ODNs in the endolysosome; therefore, 
it is important to retain the CpG ODN in the endolysosome. 
Vectors and siRNA delivery systems must deliver to the 
nucleus; therefore, breaking out from the endolysosome is 
necessary. However, for the delivery systems of CpG ODNs, 
because TLR9 exists in the endolysosome, breaking out 
from the endolysosome is not necessary but staying in is. 
Chen et al79 coated the surface of polystylene NPs with four 
types of cationic polymers – poly(ethylenimine), chitosan, 
poly(2-dimethyl-amino)ethyl methacrylate, and poly(L-
lysine) – to cause CpG ODN to bind. They reported that 
DICL ysosome
(green)
BNNS (red)
24 h
DAPI (blue)
200 nm BNNS (red)
48 h7 2 h
AB
C
Figure 7 Boron nitride nanospheres (BNNSs) as carrier for cytosine-phosphate-
guanosine  oligodeoxynucleotide  delivery:  (A)  transmission  electron  microscopic 
image  of  BNNSs;  (B)  localization  of  BNNSs  taken  up  into  cell  (BNNSs  [red] 
are  localized  in  endolysosome  [green]);  (C)  distribution  of  BNNSs  during  cell 
proliferation. Cells and BNNS were stained with DAPI (blue) and rhodamine B (red), 
respectively. BNNSs (red) were observed even in divided cells that were incubated 
for 48 and 72 hours (h). 
Reproduced with permission from Zhi et al.76 
Abbreviation: DIC, differential interference contrast.
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with poly(L-lysine), there was least escape of NPs from the   
endolysosome. This means that the type of polycation has an 
effect on the retention of NPs in the endosome. When Zhi 
et al76 added boron nitride NPs to 293XL-TLR9 cells, it was 
localized in the lysosome after 24 hours. This localization 
was maintained even after the cell division (Figure 7).
Sustained release of CpG ODNs
The increase in uptake efficiency of CpG ODNs and in 
their efficiency of delivery means that the dose of CpG 
ODN can be decreased. Furthermore, the retention of NPs 
in the endolysosome and lysosome leads to continuous 
effects by CpG ODN. Furthermore, the sustained release 
of CpG ODN by NPs also results in decreased dosage and 
continuous effects. Sokolova et al80 prepared multishell 
NPs that causes CpG ODN to be adsorbed to calcium 
phosphate (Figure 8). By using a multishell structure, 
CpG ODN can be protected from DNase. At the same 
time, calcium phosphate gradually dissolves in the acidic 
environment of the lysosome’s interior, so the slow 
release of CpG ODN can be expected. Zhu et al81 have   
reported on the enzyme-triggered sustainable release of 
CpG ODNs. They caused naturally occurring CpG ODN 
to be adsorbed by hollow mesoporous silica NPs with a 
laminated surface. Furthermore, they coated the surface 
with poly(L-lysine). By repeating the adsorption of this 
CpG ODN and poly(L-lysine), a layer-by-layer adsorption 
can be formed. By dissolving the NP surface of ploy(L-
lysine) with α-chymotrypsin, CpG ODN together with 
low-molecular-weight compounds loaded in the hollow 
NPs can be slowly released (Figure 9). Demento et al72 
controlled the rate of release of CpG ODN from NPs by 
attaching biotinylated CpG ODN to the surface of PLGA 
NPs modified with avidin-palmitate. Usually 100 µg of 
CpG ODN is administered per mouse, but with NPs, 
effects were observed with administration of 0.5 µg. By 
minimizing the release of CpG ODN, side effects including 
autoimmunity and lymphoid architectural damage that 
occur when CpG ODN is given in large amounts can be 
decreased.22
Delivery of CpG ODNs to target tissues
Bourquin et al77 reported that CpG ODN loaded on cation-
ized gelatin NPs had remarkably high antitumor effects 
compared with free CpG ODN in a mouse melanoma model. 
They investigated the localization of CpG ODN in vivo, 
and revealed that while free CpG ODN accumulated in 
splenocytes, CpG ODN delivered by NPs was selectively 
stored in APCs inside draining lymph nodes. The activation 
of adaptive immune response due to the selective transport 
to APCs inside draining lymph nodes by NPs is believed to 
be the cause for the high antitumor effect.
The size of NPs also has an effect on transferability into 
tissues. The molecular weight of drugs and the size of NPs are 
known to be factors determining the transferability into lymph 
nodes. Drugs with a molecular weight less than 5000 injected 
intramuscularly or subcutaneously are absorbed by capillar-
ies and circulated. However, drugs with a molecular weight 
greater than 20,000 mainly transfer to lymph nodes.82 The 
commonly used class B CpG ODN with phosphorothioate 
backbone has a molecular weight of about 8000, and its 
transferability to lymph nodes is low. For therapeutic NPs 
administered into the abdominal cavity of mice, it has been 
reported that NPs with sizes of 100–200 nm are excellent 
for transferring to lymph nodes and in retention.83 Kuramoto 
et al84 prepared liposomes 100–200 nm in size composed of 
N-[1-(2,3-dioleyloxy)propyl]-N,N,N-trimethylammonium 
chloride, a cationic lipid, and cholesterol, to which CpG 
ODNs were loaded. When these NPs were administered to 
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Figure  8  Multishell  calcium  phosphate  (CaP)  nanoparticles  (NPs)  for  cytosine-
phosphate-guanosine  (CpG)  delivery:  (A)  preparation  of  multishell  CaP-NPs 
functionalized  with  CpG  oligodeoxynucleotides  and  antigen  (hemagglutinin,  HA): 
(B) scanning electron micrographs of singe-shell (top panels) and triple-shell NPs 
(bottom panels). 
Reproduced with permission from Sokolova et al.80
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the abdominal cavity of mice with peritoneal dissemination, 
a pronounced antitumor effect was observed compared with 
CpG ODN alone.
By attaching specific ligands to the surface of NPs, it is 
possible to deliver them to target cells. Because macrophages 
and pDCs, which are target cells of CpG ODN, have man-
nose receptors, it is believed that introducing mannose to 
the surface of NPs can intensify the effects of CpG ODNs. 
Kuramoto et al85 loaded CpG ODN on mannose-modified 
liposome, the surface of which was modified with mannose-
modified cholesterol derivative cholesten-5-yloxy-N-(4-((1-
amino-2-β-D-thiomannosylbutyl)amino)alkyl)formamide, 
and administered it to the abdominal cavity of mice with 
peritoneal dissemination. As a result, by targeting the immune 
cells in the greater omentum and the mesentery, where 
numerous lymph nodes exist, increased antitumor effect was 
reported. Also, Chen et al86 synthesized glycodendrimers with 
terminals consisting of α-mannose and made this adsorb to 
the surface of boron nitride nanotubes. Because α-mannnose 
binds with the mannose receptor of macrophages, CpG 
ODN delivered by these NPs is selectively taken up into 
macrophages. Also, because glycodendrimer is recognized 
by lectins on the cell surface, cellular uptake efficiency can 
also be expected to increase.
Multicomponent delivery system 
including CpG ODNs
When antigens and CpG ODNs are delivered at the same 
time, the advantages of both agents can be maximally   
drawn out.87,31 Furthermore, when delivering these agents 
simultaneously with NPs, it has been reported that using sepa-
rate NPs to deliver each of the agents results in greater immu-
nostimulatory effect.88–91 This suggests that delivering antigens 
and CpG ODN to APCs at the same time is important.
Standley et al29 encapsulated ovalbumin (OVA), and 
furthermore prepared acid-degradable NPs (CpG-OVA-NPs) 
based on a cross-linked polymer network that includeed CpG 
ODN. The size of these NPs was 200–500 nm, and the bond-
ing amount of the encapsulated OVA and CpG ODN were 
40 and 25 µg/mg NPs for CpG ODN. In vitro assays showed 
CpG-OVA-NPs increased the amount of IL-12 secreted by 
APCs by 45 times compared with NPs encapsulating only 
OVA. Also, the induction of CD40, CD80, and CD86, indica-
tors of DC activation also increased. However, co-delivery 
had no effect on major histocompatibility complex (MHC) 
I and MHC II. It has been reported that for in vivo assays, 
co-delivery can induce OVA-specific CD8 T-cell response. 
Lee et al92 also showed the enhancement of MHC-restricted 
presentation of antigen by using biodegradable PLGA 
NPs loaded with CpG ODNs and OVA. Similar profound 
augmentation of anti-OVA-specific immune response was 
observed by co-delivery of OVA and CpG ODN using 
nanoliposomes.93
Nasal and intradermal vaccination is an attractive strategy 
for CpG ODN delivery. For this strategy in previous studies, 
mucoadhesive N-trimethyl chitosan NPs loaded with OVA and 
CpG ODN were prepared.94,95 This delivery system induced a 
significantly higher level of IgG2a and increased the number of 
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Figure 9 Hollow mesoporous silica/poly(L-lysine) (HMS/PLL) nanoparticles for codelivery of drug and cytosine-phosphate-guanosine (CpG) oligodeoxynucleotides (ODNs): 
(A) preparation of the fluorescein and CpG ODN-loaded HMS/PLL particles and enzyme triggered release; (B and C) transmission electron microscopic images of HMS 
nanoparticles. 
Reproduced with permission from Zhu et al.81 
Abbreviations: APTES, aminopropyltriethoxysilane; LBL, layer-by-layer.
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OVA-specific IFN-γ producing T cells in the spleen compared 
with NPs with only OVA, suggesting that the co-delivery of anti-
gen and CpG ODN improves the immunostimulatory effect.
Many studies have reported on systems that incorporate 
CpG ODN and antigens in biodegradable NPs.96–101 These 
systems co-encapsulate CpG with antigens in biodegradable 
NPs. Demento et al72 minimized the release rate of CpG ODN 
by using biotin-avidin binding to attach CpG ODN to the 
surface of biodegradable PLGA NPs. CpG ODN-modified 
antigen-encapsulating PLGA NPs that encapsulated antigen 
peptides of the West Nile virus envelope protein were prepared. 
The average size of these NPs was 272 nm, and the encap-
sulated antigen peptides were about 4.7 µg/mg NPs. These 
NPs were administered to mice, and their immunostimula-
tory effect was compared with Alhydrogel, which includes 
antigens and aluminum hydroxide (as adjuvant). The results 
showed that with Alhydrogel, the level of IgG1, associated 
with Th2-skewed response, was high. With CpG ODN-
modified antigen-encapsulating PLGA NPs, the levels of 
IgG2a and IgG2b, involved in Th1-based response, were 
high.   Concerning infection of the West Nile virus, the test 
group administered Alhydrogel had a 44% survival rate. 
The test group administered CpG ODN-modified antigen-
encapsulating PLGA NPs had a 94% survival rate.
Intratumoral injection of PEGylated unilamellar lipo-
somes bearing surface-conjugated anti-CD40 antibody and 
CpG ODN has demonstrated synergistic antitumor effects 
without dose-limiting inflammatory toxicity.102 In addi-
tion, co-delivery of polyriboinosinic-polyribocytidylic acid 
(poly(I:C)), an agonist of CpG and TLR3, with CD40 ligand 
(CD40L), has been reported to intensify the antitumor effect 
of CD40L.103 When vector-expressing CD40L (pSP-D-
CD40L) was directly administered to mouse tumor together 
with CpG ODN and poly(I:C), antitumor activity was dis-
played. When pSP-D-CD40L was loaded onto poly(β-amino 
esters), a cationic polymer, and polyethylenimine NPs, and 
delivered together with CpG ODN and poly(I:C), even 
greater antitumor effect was obtained. Wells et al104 observed 
high antitumor activity as a result of the delivery of anti-
CD40 antibody together with CpG ODN, poly(I:C9), and 
IFN-γ in an emulsion of squalene and Tween 80. These high 
antitumor activities are believed to be due to the induction 
of the powerful antitumor response of CD8-positive T cells 
by the stimulation of CD40 combined with TLR agonists. 
Also, Sokolova et al80 reported that CpG ODN and poly(I:C) 
incorporated with hemagglutinin, a model antigen, into 
multishell calcium phosphate NPs and administered to DCs 
resulted in a greater amount of IL-12 produced.
Disadvantages of delivery system
Meanwhile, the disadvantages of using NPs include not being 
able to establish the safety of NPs and not being able to clarify 
the metabolic process. When mixed with DNA, cationic 
polymers like poly(L-lysine) and polyethyleneimine form 
polyplexes.105–107 Also, the method to attach CpG ODN by 
modifying negatively charged NPs with polycation is the most 
generally implemented method. However, polycations elicit 
the nonspecific adsorption of negatively charged molecules, 
and also promote the formation of NP aggregates.108–110 These 
results are believed to be causes of side effects.   Furthermore, 
it has been suggested that polycations may cause damage to 
liver from complement activation.45 Research has been con-
ducted to avoid these disadvantages of polycations by using 
PEG111 and polyanions.112,113 Also, it has been reported that 
ionizable cationic liposome eliminates these disadvantages 
of polycations.27 Kim et al110 prepared amphiphilic NPs 
composed of hydrophilic poly(γ-glutamic acid) (γ-PGA) 
and hydrophobic L-phenylalanine. These NPs are negatively 
charged by ionizing the carboxyl group near the surface of 
γ-PGA.114 However, it has been reported that free CpG ODN 
of the same negative charge can be encapsulated. Forming 
a polyplex of CpG ODN and poly(ε-lysine), the CpG ODN 
load can be increased by encapsulating the polyplex in γ-PGA 
and hydrophobic L-phenylalanine.
Prospects for the future
Recently, a cytosolic DNA-sensing receptor that functions 
upstream of the TLR was discovered and named the high-
mobility group box (HMGB) protein.115 In addition to being 
expressed in immune cells, HMGB protein can be found 
in a variety of other cell types. The protein can recognize 
DNA and RNA and activate the innate immune system. 
Furthermore, since HMGB recognizes mammalian DNA, it 
is thought to be implicated in autoimmune diseases. Class B 
CpG ODNs with a phosphorothioate backbone demonstrated 
a high affinity to HMGB,115 whereas interaction was not seen 
with a natural CpG ODN with a phosphodiester backbone.116 
These results suggest that CpG ODNs with a phosphorothio-
ate backbone activate innate and adaptive immune systems in 
B cells and APCs via TLR9, and inhibit the innate immune 
system in other types of cells. Conversely, natural CpG ODNs 
with only a phosphodiester backbone activate the innate and 
adaptive immune systems in B cells and APCs via TLR9 and 
do not inhibit the innate immune system in other types of 
cells. From the standpoint of improvement and maintenance 
of systemic immune activation, the presence of natural CpG 
ODNs with a phosphodiester backbone is therefore more 
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advantageous than CpG ODNs with a phosphorothioate 
backbone.
The number of natural CpG ODNs consisting entirely of 
phosphodiester backbone developed is significantly smaller 
than that of CpG ODNs with a phosphorothioate backbone. 
The development of clinically applicable natural CpG ODNs 
is therefore expected to grow in the future. On the other 
hand, since CpG ODNs with a phosphorothioate backbone 
demonstrate high affinity with HMGB protein, they may be 
effective in the treatment of HMGB-mediated autoimmune 
diseases116 such as rheumatoid arthritis and systemic lupus 
erythematosus.
There are many benefits of NP-mediated delivery of CpG 
ODNs. The author found that the binding modes of CpG 
ODNs to NPs affect the production of immune mediators 
(cytokines) (unpublished data). That is, the type of the 
binding mode of class B CpG ODNs to NPs can induce the 
production of either IL-6 or IFN-α. This ability to control 
cytokine induction opens the possibility of treatment-specific 
preparations of CpG ODN carriers. Most CpG ODN NP 
preparations employ CpG ODNs with a phosphorothioate 
backbone. As described earlier in this review, natural CpG 
ODNs do not require encapsulation in NPs such as liposomes 
to be protected from DNase activity: adsorption to NPs is 
sufficient. The development of safe delivery systems for 
natural CpG ODNs in NPs is fast approaching.
Conclusion
The application of CpG ODNs for the treatment of cancers, 
infectious diseases, and allergies holds great promise, 
because CpG ODNs interact with TLR9 and activate both 
the innate and the adaptive immune system. This review 
paper summarizes the structural features that depend on base 
sequences of CpG ODNs consisting of phosphorothioate 
and phosphodiester backbones, and their relationship to the 
capacity of immune mediator cytokine induction. In addition, 
advantages and disadvantages in the delivery system of these 
CpG ODNs using various NPs and future direction of studies 
on CpG ODNs are described.
The number of natural CpG ODNs consisting entirely of 
phosphodiester backbone developed is significantly smaller 
than that of CpG ODNs with a phosphorothioate backbone. 
The development of clinically applicable natural CpG 
ODNs is therefore expected to grow in the future. From the 
standpoint of improvement and maintenance of systemic 
immune activation, the presence of natural CpG ODNs with 
a phosphodiester backbone is therefore more advantageous 
than CpG ODNs with a phosphorothioate backbone. 
However, since CpG ODNs with a phosphorothioate 
backbone demonstrate high affinity with HMGB protein, 
they may be effective in the treatment of HMGB-mediated 
autoimmune diseases116 such as rheumatoid arthritis and 
systemic lupus erythematosus.
There are many benefits of NP-mediated delivery of CpG 
ODNs, and the development of safe delivery systems for 
natural CpG ODNs in NPs is fast approaching.
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